NEW YORK (GenomeWeb) – Abbott has inked deals with Celgene and Agios Pharmaceuticals to develop and commercialize PCR-based companion diagnostic tests that will identify isocitrate dehydrogenase (IDH) mutations in patients with acute myeloid leukemia.
To read the full story....
Register for Free....and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.